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Background: Self-Monitoring of Blood Glucose (SMBG) is considered as a key factor in management of people with
diabetes which is a growing and cost demanding health problem. The purpose of this study was to investigate the
effect of comprehensive patient management using structured SMBG on metabolic control as well as its cost
consequence analysis.
Methods: Sixty subjects were recruited in an observational study for a period of 6 months. They were provided
with the ACCU-CHEK 360° View tool to fill in the values of the 7-point blood glucose profiles in three consecutive
days during the study on a monthly basis. Changes in metabolic control were assessed by HbA1c and lipid profile
measurement at the beginning and at the end of the study. In addition, cost consequence analysis was done
considering different level of health care professionals with or without insurance coverage. The Average Cost
Effectiveness Ratio (ACER) as well as Cost saving analysis were calculated and compared.
Results: The analysis showed significant reduction in HbA1c during the 6-month period in all subjects (P = 0.000).
Furthermore, a positive effect was observed on lipid profile. The cost of endocrinologist’s visit in private sector was
estimated to be 265.76 USD while this figure was149.15 USD for general practitioner in public sector with insurance
coverage. Total complications and mortality cost saving was 154.8 USD. The lowest ACER was calculated for
intervention with general practitioner in public sector with insurance coverage.
Conclusion: Structured SMBG results in significant improvement of glycemic status. Moreover, it is more cost
saving in public sector with insurance coverage. It seems that general practitioner visits with insurance coverage is
the most affordable option for people with type 2 diabetes.
Keywords: Structured self-monitoring of blood glucose, Diabetes, Cost analysisIntroduction
Diabetes is a complex and growing health problem with
significant social and economic burden [1]. In 2011, it
was estimated that there were 366 million adults with
diabetes throughout the world an increase of more than
120 million since 2007 [2]. By 2030, the number of
adults with diabetes is expected to rise to 552 million
[2]. The prevalence of type 2 diabetes mellitus (T2DM)
in Iran was reported to be 7.7% in people younger than
65 years [3].* Correspondence: farshchi_a@razi.tums.ac.ir
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reproduction in any medium, provided the orThere are many risk factors for development of dia-
betes [4]. Diabetes is associated with a decrease in life
expectancy [2] and people with diabetes are at increased
risk for developing various cost-demanding complica-
tions [5]. Therefore, diabetes has a profound impact on
the physical, psychological, and financial well-being of
individuals, their families, and the society [5].
The benefits of strict glycemic control on reducing the
risk of micro and macrovascular complications are well
documented [6-8]. For example, the United Kingdom
Prospective Diabetes Study (UKPDS) demonstrated that
every percentage point decrease in HbA1c is associated
with significant reduction in diabetes related deaths
(21%), myocardial infarction (14%) and microvasculartd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(SMBG) enables people with diabetes to modify their be-
havior and adjust their treatment according to the
results obtained by blood glucose monitoring [9]. It also
helps them to be active in diabetes educational programs
through a deep understanding of the patterns provided
by SMBG [9,10]. However, the cost of SMBG is a major
problem. It was reported to be around £90 million in the
UK in 2001 [8].
Since the first description of structured SMBG [11]
there has been controversial issues regarding its indica-
tions, frequencies and cost effectiveness in people with
type 2 diabetes [12]. The results of several studies sup-
ported the cost effectiveness of structured SMBG for gly-
cemic control in diabetic people [13,14]; however, other
studies did not support the issue [15,16]. The role of the
general practitioner as gatekeepers between primary and
secondary care has great importance in cost-effectiveness
of the intervention [17,18]. In addition, health insurance
coverage is the other noteworthy factor to cost effective
healthcare [19].
The aim of this observational study was to investigate
the effect of comprehensive patient management using
structured SMBG on metabolic control as well as its cost
consequence analysis considering different level of
health care professionals with or without insurance
coverage in people with type 2 diabetes.
Methods
We performed a 6-month observational study, exploring
the effect of a comprehensive approach in diabetes man-
agement. People with uncontrolled type 2 diabetes
(HbA1c ≥ 8) were recruited from the outpatient diabetes
services at Institute of Endocrinology and Metabolism
(IEM).
Exclusion criteria included pregnancy, previous use of
self-monitoring of blood glucose, and far advanced
complications.
At enrollment, basic education was provided to the eli-
gible subjects. People participated in two face-to-face
educational sessions; ACCU-CHEKW Assist was used for
this purpose. All participants received education about
the meter device as well as essential instructions in order
to record the results. Instructions were provided how to
use the ACCU-CHEKW 360° View paper tool, and to fill
in the values of the 7-point blood glucose profiles in
three consecutive days, for 6 months during the study
on a monthly basis. Seven-point SMBG includes three
pre-meals, three post-meals, and bedtime blood glucose
values during each day.
All people were supplied with ACCU-CHEKW Per-
forma glucometers, strips, lancets, and lancing devices,
plus the 360° View forms and were asked to record their
blood glucose values at the end of each month on 3consecutive days. During the study, physicians were free
to adjust the medical treatment of all diabetic people
when needed.
Changes in metabolic control were assessed by HbA1c
and lipid profile measurement at enrollment and at the
end of the study. HbA1c was measured using ion ex-
change chromatography (DS5 Analyser, Drew Scientific
limited, Cumbria, United Kingdom).
Ethical approval was granted from the ethics board at
IEM.
All data are presented as mean ± standard deviation
(SD). Significant differences in general characteristics
were determined by Chi-square and Student’s t-test.
SPSS for Windows (Version 19; SPSS Inc., Chicago, IL)




We calculated direct costs of intervention. Resources
used as costs of the intervention were: patient educa-
tion, laboratory tests, glucometer price, test strips and
physician visits during the study. We considered three
main levels of healthcare professionals to calculate
and compare the direct costs of the intervention in
public and private sectors. All tariffs data were gath-
ered from the official website of Ministry of Health
(MoH) of Iran [20]. Costs from health provider per-
spective, were converted from Iranian Rials (IRR) into
USA dollar (USD) at an official exchange rate of
9,920 IRR/1USD 2010 [21] to have an international
comparison.
Average cost effectiveness analysis
Average changes in HbA1c from beginning to the end of
the study were considered as clinical outcome (effect)
and the Average Cost Effectiveness Ratio (ACER) was
calculated according to the below formula for each pa-
tient: ACER=Cost/ Outcome [22].
The comparison of ACERs was held afterwards. We
used sensitivity analyses to examine the effects of costs
of these types of visits on the main results.
Cost saving
With this technique, we evaluated cost saving related out-
come improvement in SMBG intervention. Changing in
HbA1c mentioned as standard indicator of intervention
efficacy and linked to money saved according to two pre-
viously published evidences. Health care expenditures
attributed to T2DM complications were extracted from
the study conducted by Javanbakht et al. [23] and were
linked to Stratton’s study [7] to estimate the monetary
benefits of changes in HbA1c. Finally, Cost saving for each
alternative approaches were reported.
Table 1 Baseline characteristics of the participants
Variables
Age 52.7 (± 7.9)





Diet ± Oral agent 45 (75%)
Diet ± Insulin 10 (16.70%)
Insulin ± Oral agent ± Diet 5 (8.30%)
Mean ± SD are shown for continuous variables and % is shown for categorical
variables.
DM; Diabetes Mellitus.
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Sixty subjects were included in this study. Thirty three
(55%) were female and 27 (45%) were male. The mean
age was 52.7 [±7.9 SD], and the mean duration of dia-
betes was 9.0 [±7.1 SD] years. Table 1 illustrates baseline
characteristics of the participants.
HbA1c as the primary end point was improved signifi-
cantly from 10.2% to 8.5% (P = 0.000). In addition, we
observed a positive effect of structured SMBG on BMI,
waist circumference, blood pressure as well as metabolic
outcomes (Tables 2 and 3).Consequences cost analysis
Costs
According to our data from cost resources and also
MoH defined tariffs, different hypothesis of costs were
compared. Table 4 shows the direct cost of intervention
in public and private sectors. Total costs per patient
with different type of visit and lab test tariffs are pre-
sented in Table 5. The highest and the lowest cost were
related to endocrinologist in private sector (265.76 USD)
and general practitioner in public sector with insurance





BMI (kg/m2) 28.9 (± 5.0) 28.6
Waist Circumference (cm) 98.9 (± 11.2) 97.2
Systolic Blood Pressure (mmHg) 124.6 (± 15.5) 122.7
Diastolic Blood Pressure (mmHg) 79.0 (± 5.4) 78.3
Data are shown as Mean ± SD.
P < 0.05 is considered as statistically significant.
NS; Not Significant.
BMI; Body Mass Index.Average cost effectiveness analysis
ACER was also calculated for 1.7% improvement in
HbA1c as the main outcome per patients with different
type visits and lab test tariffs (Table 6).
As demonstrated in Table 6, the most cost effective al-
ternative is intervention with general practitioner in
public sector with insurance coverage. In addition, the
sensitivity analysis describes the effects of costs in differ-
ent types of visit and lab test tariffs on the main results
(Figure 1). Results indicate the mean ACER in private
sector, public sector without insurance and with insur-
ance coverage are 143.28, 105.82 and 88.63 USD per 1%
reduction in HbA1c, respectively. Moreover, mean
ACER results in different levels of healthcare profes-
sionals are demonstrated in Table 6.
Cost saving
In Javanbakht et al. study [23], total annual cost of dia-
betes related complications and mortality reported to be
879.8 USD (440 USD for 6 month). As shown in Table 7,
total complications and mortality cost saving was 154.8
USD. Hence, according to our calculation the public sec-
tor with insurance coverage could be chosen as the
highest cost saving alternative.
Discussion
Poor glycemic control results in unfavorable clinical out-
comes for people with diabetes. Subsequently, medical
costs related to the treatment of diabetic complications
will increase. Furthermore, the greatest numbers of
people with diabetes are among economically productive
age group [2,3]; therefore, it is important to manage the
disease in order to ultimately prevent the complications.
Considering the findings of the study conducted by
Javanbakht et al. [23], T2DM and its complications im-
pose a large economic burden on the individual and
health care system in Iran which can mostly be pre-
vented through improved lifestyle and prevention pro-
grams. Improved understanding of the economic burden
of diabetes also helps health care policy makers for fu-






(±1.1) -0.3 -0.07, 0.72 NS
(± 5.2) -1.7 -2.71, 2.32 NS
(± 15.2) -1.9 0.21, 10.87 0.042
(± 8.2) -0.7 0.16, 4.39 0.035








HbA1c 10.2 (± 1.6) 8.5 (± 2.0) -1.7 1.10, 2.30 0.000
HDL 39.9 (± 8.9) 43.0 (± 8.6) 3.1 -5.69, -0.52 0.019
LDL 86.7 (± 28.9) 83.9 (± 27.2) -2.8 -5.35, 10.95 NS
TG 129.6 (± 62.6) 122.4 (± 43.6) -7.2 -5.91, 20.26 NS
HDL/LDL ratio 0.5 (± 0.2) 0.6 (± 0.1) 0.1 -0.09, -0.014 0.009
Data are shown as Mean ± SD.
P < 0.05 is considered as statistically significant.
NS; Not Significant.
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duce its associated complications and medical costs, ac-
curate blood glucose measurements are essential [24].
SMBG is widely considered as a key component in man-
agement of people with diabetes [25]; thus, we were to
investigate the effect of comprehensive patient manage-
ment using structured SMBG on metabolic control asTable 4 Direct costs of the intervention in public and
private sectors






Patient education 4 221.77 886.72 14.78
Lab tests
Private 120 15.12 1814.4 30.24
Public
- Insured 120 1.71 205.2 3.42
- Uninsured 120 6.86 823.2 13.72
Glucometer device 60 58.47 3508.2 58.47
Test Strips and lancets 126 29.03 3657.78 60.96
Educational tool 60 4.54 272.4 4.54
Physician visits
General Practitioner
- Private 360 8.06 2903.23 48.38
- Public
- Insured 360 1.11 402.82 6.71
- Uninsured 360 3.72 1342.74 22.37
Internist
- Private 360 13.10 4717.74 78.62
- Public
- Insured 360 1.34 484.48 8.07
- Uninsured 360 4.48 1614.92 26.91
Endocrinologist
- Private 360 16.12 5806.45 96.77
- Public
- Insured 360 1.64 593.35 9.88
- Uninsured 360 5.49 1977.82 32.96
USD; USA dollars.well as its cost consequence analysis in people with type
2 diabetes in Iran.
We found that structured SMBG contributes signifi-
cantly in improvement of metabolic outcomes in
people with type 2 diabetes. Furthermore, the ACER
showed subtractive manner per 1% reduction of
HbA1c per patient, from private to public sector con-
sidering the state of insurance coverage. In addition,
considering the level of health care professionals, a
slight reduction in ACER was observed from subspeci-
alty level to the general practitioner level. According
to Table 6, the most cost effective hypothesis is the
visit by the general practitioners in people with insur-
ance coverage in the public sector and the lowest cost
effective hypothesis is attributed to subspecialty visits
in the private sector. Many studies have discussed the
role of the general practitioners as the “gatekeeper”
and vital elements of health care services since restrict
direct access to specialists [26]. Kerr et al. reported
that only six percent of patients are allowed to self-
refer to subspecialists in USA and the “gatekeeper” is
required in sixty percent of cases to acquire prescribed
pre-authorization [27]. A result of this plan is that
patients are being managed by generalists prior to be
managed by internists or endocrinologists. So, it would
be more effective to implement this result in global
health systems. One of the negative effects of imbal-
anced supply and demand for physician visits is “sup-
ply surplus” for general practitioner visits and also
“demand surplus” for specialist visits. In diabetes sce-
nario, according to disease complexity, the growingTable 5 Total costs of intervention per patient in USD
considering public and private sectors







General Practitioner 217.37 174.84 149.15
Internist 247.61 179.38 150.51
Endocrinologist 265.76 185.43 152.32
USD; USA dollars.
Table 6 ACER per 1% HbA1c reduction per patient
considering public and private sectors







General practitioner 127.86 102.85 87.74
Internist 145.65 105.52 88.54
Endocrinologist 156.33 109.08 89.60
Mean 143.28 105.82 88.63
ACER; Average Cost Effectiveness Ratio.
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cessibility and affordability of the related health care
services are vital. We show that the same metabolic
outcome can be achieved regardless of the level of
health care professionals.
There are some evidences which are in favor of more
effective health seeking behavior and also better use of
existing health resources with affordable prices in the
public sector [28]. On the other hand, there are some
barriers, namely economic issues which put some limita-
tions on the process of patient referral [29]. This study
directs cost-effectiveness of SMBG with public sector ra-
ther than private sector.
Our study illustrated all SMBG with public sector with
insurance coverage are cost beneficial. Differences in
ratios are negligible and indicate the importance of in-
surance to reach equity in health care services. We
demonstrated general practitioner visits with insurance


















Figure 1 Sensitivity analysis of effects of costs considering the level o
Average Cost Effectiveness Ratio.Conclusion
The quality of health care provided in public sectors
and the insurance coverage are key factors to make
health services accessible and also affordable. One of
the main limitations in applying SMBG is some unin-
sured costs of care (for example costs of glucometer,
strips and even education). If health care services are
to be moved from internists to generalists, additional
consideration should be given to have adequate know-
ledge in generalists and also efficient system resources
to supply satisfactory quality of care for people with
diabetes. All in all, the 6-month implementation of
the comprehensive approach for diabetes management
using structured self-monitoring of blood glucose and
educational sessions resulted in significant improve-
ment of glycemic status in all subjects in the current
study.r with insurance
verage
Public sector with insurance
coverage
Internist Endocrinologist
f health care professionals in public and private sectors. ACER;
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